FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
Severe eosinophilic asthma (SEA) has been associated with T‐helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for severe cases. Mepolizumab, an IL‐5 antagonist, is indicated...
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined. NUCALA is indicated for the add-on treatment of patients 6+ with severe eosinophilic asthma (SEA). Not for acute bronchospasm or status asthmaticus....
Asthma flares were markedly decreased after 6 months. The ACT was 23. The FVC and FEV1 were further improved (Table 1). 3. Discussion There are a number of unresolved issues related to the anti-IL-5 strategy in the treatment of eosinophilic asthma. Yancey et al. reported that mepolizumab ...
Asthma is a heterogeneous disease and this is particularly true of severe refractory asthma. Biologic treatments have shown promise in several phenotypes of severe asthma. Anti-IgE hMabs are effective in severe allergic asthma and hMabs directed against IL-5 in severe eosinophilic asthma, particularly...
identified just one paper evaluating the long-term clinical and economic impact of adding MEP to standard treatments with ICS and other controller medications on severe eosinophilic asthmatic US patients5. Despite the significant improvement in quality of life, the estimated cost-effectiveness of MEP ...
secondary endpoints were pre-bronchodilator forced expiratory volume in 1 s (FEV) and total asthma symptom score. This study is registered with, number. Mepolizumab treatment in patients with severe eosinophilic asthma 2014, New England Journal of Medicine...
Tezepelumab is an add-on medicine for the treatment of people aged 12 years or older with severe asthma that is not controlled with their current medicines. In this article, we discuss how tezepelumab may work in different types of asthma, for example allergic asthma, eosinophilic asthma, ...
The present study investigated the characteristics of EETs from patients with non-severe asthma (NSA, n = 20) and severe eosinophilic asthma (SEA, n = 20) and evaluated EET function. The percentage of EET-forming peripheral blood eosinophils stimulated with IL-5 and LPS was ...